AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:AVEO
- CUSIP: 05358810
- Web: www.aveopharma.com
Capitalization:- Market Cap: $278.11 million
- Outstanding Shares: 110,362,000
Average Prices:- 50 Day Moving Avg: $1.65
- 200 Day Moving Avg: $0.93
- 52 Week Range: $0.50 - $3.19
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 22.55
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $3.84 million
- Price / Sales: 71.28
- Book Value: $0.04 per share
- Price / Book: 62.00
Profitability:- EBIDTA: ($29,880,000.00)
- Net Margins: -728.85%
- Return on Equity: -836.92%
- Return on Assets: -87.50%
Debt:- Debt-to-Equity Ratio: 2.16%
- Current Ratio: 2.52%
- Quick Ratio: 2.52%
Misc:- Average Volume: 5.31 million shs.
- Beta: 1.37
- Short Ratio: 0.42
Frequently Asked Questions for AVEO Pharmaceuticals (NASDAQ:AVEO)
What is AVEO Pharmaceuticals' stock symbol?
AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
How were AVEO Pharmaceuticals' earnings last quarter?
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its earnings results on Thursday, May, 4th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.00. The business earned $2.53 million during the quarter. AVEO Pharmaceuticals had a negative return on equity of 836.92% and a negative net margin of 728.85%. View AVEO Pharmaceuticals' Earnings History.
Where is AVEO Pharmaceuticals' stock going? Where will AVEO Pharmaceuticals' stock price be in 2017?
2 brokerages have issued 12-month target prices for AVEO Pharmaceuticals' shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $2.50 in the next year. View Analyst Ratings for AVEO Pharmaceuticals.
Are investors shorting AVEO Pharmaceuticals?
AVEO Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totalling 3,657,353 shares, an increase of 63.9% from the June 15th total of 2,231,389 shares. Based on an average daily trading volume, of 16,762,289 shares, the short-interest ratio is presently 0.2 days. Currently, 4.2% of the company's stock are short sold.
Who are some of AVEO Pharmaceuticals' key competitors?
Some companies that are related to AVEO Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Seres Therapeutics (MCRB), AnaptysBio (ANAB), Dynavax Technologies Corporation (DVAX), Sucampo Pharmaceuticals (SCMP), Ignyta (RXDX), CytomX Therapeutics (CTMX), Atara Biotherapeutics (ATRA), Progenics Pharmaceuticals (PGNX), Reata Pharmaceuticals (RETA), BioCryst Pharmaceuticals (BCRX), Geron Corporation (GERN), Karyopharm Therapeutics (KPTI), MyoKardia (MYOK), Jounce Therapeutics (JNCE), G1 THERAPEUTICS (GTHX), Adaptimmune Therapeutics PLC (ADAP) and Bellicum Pharmaceuticals (BLCM).
Who are AVEO Pharmaceuticals' key executives?
AVEO Pharmaceuticals' management team includes the folowing people:
- Michael P. Bailey, President, Chief Executive Officer, Director
- Matthew Dallas, Chief Financial Officer
- Michael N. Needle M.D., Chief Medical Officer
- Henri A. Termeer, Lead Out Side Director
- Kenneth M. Bate, Independent Director
- Anthony B. Evnin Ph.D., Independent Director
- Robert C. Young M.D., Independent Director
How do I buy AVEO Pharmaceuticals stock?
Shares of AVEO Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AVEO Pharmaceuticals' stock price today?
One share of AVEO Pharmaceuticals stock can currently be purchased for approximately $2.48.
MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for AVEO Pharmaceuticals (NASDAQ:AVEO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $2.50 (0.81% upside) |
Analysts' Ratings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/13/2017 | FBR & Co | Reiterated Rating | Outperform | $3.00 | High |  |
| 6/24/2017 | Piper Jaffray Companies | Set Price Target | Buy | $2.00 | High | |
(Data available from 7/22/2015 forward)
Earnings History for AVEO Pharmaceuticals (NASDAQ:AVEO)Earnings History by Quarter for AVEO Pharmaceuticals (NASDAQ AVEO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2017 | Q1 2017 | ($0.12) | ($0.12) | | $2.53 million | View | N/A | |
| 11/4/2016 | Q3 2016 | ($0.12) | ($0.07) | | $0.99 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.12) | ($0.13) | $1.00 million | $1.20 million | View | N/A | |
| 3/15/2016 | Q415 | ($0.04) | ($0.11) | | $3.60 million | View | N/A | |
| 11/9/2015 | Q315 | ($0.09) | $0.14 | | $15.16 million | View | N/A | |
| 8/10/2015 | Q2 | ($0.16) | ($0.10) | | $0.13 million | View | Listen | |
| 5/7/2015 | Q115 | ($0.27) | ($0.21) | | $0.13 million | View | N/A | |
| 3/6/2015 | Q314 | ($0.28) | ($0.27) | | $0.12 million | View | Listen | |
| 11/5/2014 | Q3 2014 | ($0.27) | ($0.28) | $0.33 million | $0.87 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.38) | ($0.35) | $0.35 million | $1.85 million | View | N/A | |
| 5/7/2014 | Q1 2014 | ($0.33) | ($0.12) | $0.38 million | $15.29 million | View | N/A | |
| 3/13/2014 | Q413 | ($0.33) | ($0.32) | $0.14 million | $0.32 million | View | Listen | |
| 11/4/2013 | Q313 | ($0.47) | ($0.47) | $0.23 million | $0.32 million | View | N/A | |
| 8/1/2013 | Q213 | ($0.56) | ($0.62) | $4.30 million | $0.32 million | View | N/A | |
| 4/29/2013 | Q1 2013 | ($0.72) | ($0.69) | $2.52 million | $0.32 million | View | Listen | |
| 2/13/2013 | Q4 2012 | ($0.77) | ($0.49) | $14.49 million | $15.53 million | View | N/A | |
| 10/30/2012 | Q312 | ($0.87) | ($0.69) | $6.57 million | $1.02 million | View | N/A | |
| 8/2/2012 | | ($0.82) | ($0.68) | | | View | N/A | |
| 5/3/2012 | | ($0.78) | ($0.77) | | | View | N/A | |
| 2/14/2012 | | ($0.64) | ($0.58) | | | View | N/A | |
| 11/2/2011 | | ($0.46) | ($0.55) | | | View | N/A | |
| 7/28/2011 | | ($0.80) | ($0.16) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)2017 EPS Consensus Estimate: ($0.55)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.13) | ($0.13) | ($0.13) |
| Q2 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
| Q3 2017 | 1 | ($0.17) | ($0.17) | ($0.17) |
| Q4 2017 | 1 | ($0.15) | ($0.15) | ($0.15) |
(Data provided by Zacks Investment Research)
Dividend History for AVEO Pharmaceuticals (NASDAQ:AVEO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for AVEO Pharmaceuticals (NASDAQ:AVEO)Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 50.96%
Insider Trades by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/28/2017 | Equity Opportunities Iv Growth | Major Shareholder | Buy | 6,000,000 | $0.50 | $3,000,000.00 | |
| 1/16/2015 | Matthew D Dallas | VP | Sell | 3,075 | $0.82 | $2,521.50 | |
| 1/7/2015 | Michael P Bailey | CEO | Sell | 4,484 | $0.80 | $3,587.20 | |
| 1/30/2014 | Joseph Vittiglio | SVP | Sell | 5,430 | $1.64 | $8,905.20 | |
| 3/14/2013 | David Brannon Johnston | CFO | Sell | 1,061 | $7.34 | $7,787.74 | |
| 3/7/2013 | Henri A Termeer | Director | Buy | 55,499 | $6.73 | $373,508.27 | |
| 12/13/2012 | Ngoc Tuan Ha | CEO | Buy | 75,000 | $6.65 | $498,750.00 | |
| 12/13/2012 | Robert C Young | Director | Buy | 2,371 | $6.78 | $16,075.38 | |
| 12/3/2012 | Robert C Young | Director | Buy | 1,250 | $6.41 | $8,012.50 | |
| 9/13/2012 | David Brannon Johnston | CFO | Sell | 1,386 | $10.60 | $14,691.60 | |
| 8/8/2012 | Robert C Young | Director | Buy | 1,000 | $8.63 | $8,630.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for AVEO Pharmaceuticals (NASDAQ:AVEO)
Latest Headlines for AVEO Pharmaceuticals (NASDAQ:AVEO)
| Source: |
|
| Date | Headline |
|---|
 | Here's Why AVEO Oncology Rose as Much as 15% Today
finance.yahoo.com - July 19 at 5:26 PM |
 | AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - July 17 at 10:56 AM |
| AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Short Interest Up 63.9% in June
www.americanbankingnews.com - July 16 at 7:06 AM |
 | Stock Performance Review on Biotech Industry -- Athersys, AVEO Pharma, Heat Biologics, and Ignyta
www.bizjournals.com - July 14 at 3:10 AM |
| AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Given "Outperform" Rating at FBR & Co
www.americanbankingnews.com - July 13 at 9:02 PM |
| Here's Why AVEO Oncology Fell as Much as 12.7% Today
finance.yahoo.com - July 11 at 5:15 PM |
 | AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8% - Nasdaq
www.nasdaq.com - July 11 at 2:17 AM |
| AVEO Pharmaceuticals Regulatory Decision from European Commission Expected Soon
finance.yahoo.com - July 10 at 9:15 PM |
 | Why AVEO Pharmaceuticals, Inc. (AVEO) Stock Is Soaring Today
investorplace.com - July 7 at 1:51 PM |
| AVEO Pharmaceuticals, Inc. (AVEO) Rating Reiterated by FBR & Co
www.americanbankingnews.com - June 30 at 5:20 PM |
| 2 Biotech Stocks on Analysts’ Radar: Cara Therapeutics Inc (CARA) and AVEO Pharmaceuticals, Inc. (AVEO)
finance.yahoo.com - June 30 at 4:19 PM |
| Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Cara Therapeutics
finance.yahoo.com - June 28 at 4:21 PM |
 | BRIEF-Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings
www.reuters.com - June 28 at 1:56 AM |
 | AVEO's Kidney Cancer Candidate Gets CHMP Recommendation
www.zacks.com - June 28 at 1:56 AM |
| Here's Why AVEO Oncology Rose As Much As 13.8% Today
finance.yahoo.com - June 27 at 8:55 PM |
| BRIEF-Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings - Reuters
www.reuters.com - June 27 at 3:53 PM |
 | Aveo Comeback Highlights A Transatlantic Split - Seeking Alpha - Seeking Alpha
seekingalpha.com - June 27 at 3:53 PM |
| AVEO Oncology Announces $14M in Aggregate Gross Proceeds from Hercules Credit Facility and At-the-market Stock Offerings
finance.yahoo.com - June 27 at 3:53 PM |
| AVEO's Kidney Cancer Candidate Gets CHMP Recommendation
finance.yahoo.com - June 27 at 3:53 PM |
| Piper Jaffray Companies Analysts Give AVEO Pharmaceuticals, Inc. (AVEO) a $2.00 Price Target
www.americanbankingnews.com - June 26 at 12:26 AM |
 | UPDATE 1-EU regulators greenlight U.S. biotech Aveo's kidney cancer drug
www.businessinsider.com - June 25 at 4:00 PM |
| AVEO Pharmaceuticals, Inc. (AVEO) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - June 24 at 10:22 PM |
 | AVEO Pharma surges 48% on recommendation for European approval of its cancer drug - MarketWatch
www.marketwatch.com - June 23 at 4:20 PM |
| AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma
finance.yahoo.com - June 23 at 4:20 PM |
| EU regulators greenlight U.S. biotech Aveo's kidney cancer drug
finance.yahoo.com - June 23 at 4:20 PM |
| AVEO Pharma surges 48% on recommendation for European approval of its cancer drug
finance.yahoo.com - June 23 at 4:20 PM |
| AVEO Pharmaceuticals, Inc. (AVEO) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - June 23 at 11:35 AM |
| AVEO Reaches Enrollment Target in Pivotal Tivozanib Study
finance.yahoo.com - June 21 at 4:39 PM |
| AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches Enrollment Target
finance.yahoo.com - June 20 at 4:24 PM |
| AVEO Pharmaceuticals, Inc. (AVEO) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 12 at 11:36 PM |
| Why Is AVEO Pharmaceuticals (AVEO) Up 25% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - June 9 at 9:19 PM |
| Why Is AVEO Pharmaceuticals (AVEO) Up 25% Since the Last Earnings Report?
finance.yahoo.com - June 9 at 4:18 PM |
| BRIEF-Aveo Oncology announces phase 1/2 tinivo trial
www.reuters.com - June 8 at 4:28 PM |
| AVEO Oncology Announces Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in RCC Advances to Phase 2
finance.yahoo.com - June 8 at 4:28 PM |
| AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting
finance.yahoo.com - June 5 at 6:06 PM |
| AVEO Pharmaceuticals, Inc. (AVEO) Short Interest Update
www.americanbankingnews.com - May 30 at 2:44 PM |
| Q2 2017 Earnings Forecast for AVEO Pharmaceuticals, Inc. Issued By FBR & Co (AVEO)
www.americanbankingnews.com - May 24 at 8:08 AM |
| AVEO Pharmaceuticals, Inc. (AVEO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 23 at 1:16 PM |
| AVEO Pharmaceuticals, Inc. (AVEO) Stock Rating Reaffirmed by FBR & Co
www.americanbankingnews.com - May 22 at 11:30 AM |
| AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma
finance.yahoo.com - May 19 at 9:21 AM |
 | CFO Moves: AVEO Pharmaceuticals, Community Health Systems
blogs.wsj.com - May 18 at 12:01 PM |
| BRIEF-Aveo appoints Matthew Dallas chief financial officer
www.reuters.com - May 16 at 12:28 PM |
| AVEO Announces Appointment of Matthew Dallas as Chief Financial Officer
finance.yahoo.com - May 16 at 12:28 PM |
| AVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer
finance.yahoo.com - May 15 at 4:13 PM |
| AVEO Oncology Announces Receipt of USPTO Notice of Allowance Related to AV-353
finance.yahoo.com - May 8 at 10:43 AM |
| AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected
finance.yahoo.com - May 5 at 8:48 PM |
| AVEO Pharmaceuticals, Inc. (AVEO) Announces Earnings Results
www.americanbankingnews.com - May 5 at 3:58 PM |
| AVEO Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 4 at 8:49 PM |
 | AVEO reports 1Q loss
marketbeat.com - May 4 at 9:12 AM |
| AVEO Pharmaceuticals (AVEO) Getting Somewhat Favorable News Coverage, Study Shows
www.americanbankingnews.com - May 4 at 1:01 AM |
AVEO Pharmaceuticals (AVEO) Chart for Saturday, July, 22, 2017
